Diversified Trust Co Increases Stake in Johnson & Johnson (NYSE:JNJ)
Diversified Trust Co Increases Stake in Johnson & Johnson (NYSE:JNJ)
Diversified Trust Co boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 10.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 130,708 shares of the company's stock after purchasing an additional 12,381 shares during the period. Johnson & Johnson makes up about 1.0% of Diversified Trust Co's portfolio, making the stock its 16th biggest position. Diversified Trust Co's holdings in Johnson & Johnson were worth $23,090,000 as of its most recent filing with the Securities and Exchange Commission.
根據該公司最近在證券交易委員會提交的文件中，多元化信託公司在第四季度將其莊臣公司（NYSE：JNJ-獲得評級）的股份增加了 10.5％ 的股份權益。該基金在期間內額外購買 12,381 股股份後，擁有該公司股票的 130,708 股。強生佔多元化信託公司投資組合的 1.0% 左右，使該股成為其第 16 大地位。截至最近向證券交易委員會提交的文件，多元化信託公司在強生公司的持有價值 23,090,000 美元。
A number of other hedge funds have also bought and sold shares of JNJ. Lowe Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 15.5% during the fourth quarter. Lowe Wealth Advisors LLC now owns 1,134 shares of the company's stock valued at $200,000 after buying an additional 152 shares during the last quarter. AHL Investment Management Inc. grew its stake in Johnson & Johnson by 4.7% during the 4th quarter. AHL Investment Management Inc. now owns 13,934 shares of the company's stock valued at $2,461,000 after purchasing an additional 621 shares during the last quarter. Steigerwald Gordon & Koch Inc. increased its holdings in shares of Johnson & Johnson by 2.3% in the fourth quarter. Steigerwald Gordon & Koch Inc. now owns 95,949 shares of the company's stock valued at $16,949,000 after purchasing an additional 2,145 shares during the period. Douglas Lane & Associates LLC raised its stake in shares of Johnson & Johnson by 10.4% in the fourth quarter. Douglas Lane & Associates LLC now owns 397,698 shares of the company's stock worth $70,253,000 after purchasing an additional 37,478 shares during the last quarter. Finally, AMI Asset Management Corp lifted its holdings in shares of Johnson & Johnson by 14.4% during the fourth quarter. AMI Asset Management Corp now owns 4,716 shares of the company's stock worth $833,000 after purchasing an additional 592 shares during the period. Institutional investors and hedge funds own 67.94% of the company's stock.
許多其他對沖基金也買賣了 JNJ 的股票。勞財富顧問有限責任公司增長了約翰遜的股份持有 & 約翰遜 15.5% 在第四季度.在上個季度額外購買 152 股後，勞威財富顧問有限責任公司現在擁有該公司股票的 1,134 股價值 20 萬美元。AHL 投資管理公司在第四季度增長了 4.7％ 在約翰遜的股份。艾哈林投資管理股份有限公司現在擁有該公司股票的 13,934 股股份，價值為 2,461,000 美元，在上一季度額外購買 621 股後。施泰格瓦爾德戈登和科赫公司. 在第四季度增加了其持有的約翰遜 & 約翰遜的股份 2.3%.施泰格瓦爾德戈登科赫公司現在擁有該公司 95,949 股股票，價值為 16,949,000 美元，在此期間額外購買 2,145 股股票後。道格拉斯巷 & 聯營有限責任公司提出了約翰遜股份的股份 & 約翰遜 10.4% 在第四季度.道格拉斯巷 & 聯營有限責任公司現在擁有該公司股票的 397,698 股價值 $70,253,000 在上一季度購買了額外的 37,478 股股票。最後，AMI 資產管理公司在第四季度取消了其對約翰遜公司股份的持有量 14.4％。AMI 資產管理公司在期內額外購買 592 股股票後，現在擁有該公司股票的 4,716 股價值 833,000 美元。機構投資者和對沖基金擁有公司股票的 67.94％。
Analyst Ratings Changes
分析師等級變更
JNJ has been the subject of several research reports. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. Guggenheim began coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a "neutral" rating and a $161.00 price objective for the company. Piper Sandler lowered their target price on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Finally, Atlantic Securities boosted their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a "neutral" rating in a report on Wednesday, January 25th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $174.73.
JNJ 一直是幾個研究報告的主題。摩根士丹利將約翰遜公司股票的價格目標從 176.00 美元提高至 180.00 美元，並在 1 月 25 日（週三）的研究報告中給予該公司「同等權重」評級。坎特·菲茨杰拉德在 2 月 1 日（星期三）的一份報告中重申了「超重」評級，並對約翰遜的股票發布了 215.00 美元的目標價格。古根海姆開始覆蓋約翰遜 & 約翰遜在研究筆記上週二, 2 月 28 日.他們為公司設定了「中立」的評級和 161.00 美元的價格目標。派珀·桑德勒降低了他們對約翰遜的目標價格從 $55.00 至 $52.00 在研究報告週一, 2 月 6 日.最後，大西洋證券將強生的價格目標從 160.00 美元提高到 168.00 美元，並在 1 月 25 日（星期三）的一份報告中給予該公司「中立」評級。七位投資分析師對該股票進行了保持評級，其中六名已發出買入評級，其中一名為該公司分配了強大的買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為「適度買入」，平均目標價為 174.73 美元。
Insiders Place Their Bets
內部人士下注
In other news, insider James D. Swanson sold 1,062 shares of the firm's stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company's stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.35% of the stock is currently owned by corporate insiders.
在其他消息中，內幕詹姆斯·斯旺森在 3 月 6 日（星期一）的交易中出售了公司股票的 1,062 股。這些股份以平均價格 154.66 美元出售，總價值為 164,248.92 美元。交易後，內幕人士現直接擁有該公司股票的 9,215 股股份，價值為 1,425,191.90 美元。該交易在與 SEC 合法提交的文件中披露，該文件可通過以下方式訪問 這個鏈接。0.35％ 的股票目前由企業內部人士擁有。
Johnson & Johnson Stock Performance
強生股票表現
NYSE:JNJ opened at $152.65 on Friday. The company has a fifty day moving average of $159.76 and a two-hundred day moving average of $167.55. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $186.69. The stock has a market capitalization of $397.54 billion, a PE ratio of 22.65, a P/E/G ratio of 2.60 and a beta of 0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99.
紐約證交所代碼：新澤西州週五以 152.65 美元開市。該公司有一個五十天移動平均線為 159.76 美元，兩百天移動平均線為 167.55 美元。約翰遜擁有五十二周低點 150.11 美元，五十二周高點為 186.69 美元。該股的市值為 397.54 億美元，私募股票比率為 22.65，盈利/英克比率為 2.60，貝塔值為 0.54。該公司的債務與權益比率為 0.35，快速比率為 0.77，流動比率為 0.99。
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion for the quarter, compared to analysts' expectations of $23.90 billion. During the same period in the previous year, the firm posted $2.13 EPS. Johnson & Johnson's revenue was down 4.4% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.
強生公司 (紐約證交所代碼:JNJ — 獲取評分) 上次公佈其季度收益數據，週二，1 月 24 日。該公司報告了該季度的每股盈利 2.35 美元，超過了 2.22 美元的共識估計高出 0.13 美元。強生的股權回報率為 35.76％，淨利潤率為 18.90％。該公司本季度的營收為 237.1 億美元，而分析師的預期為 233.9 億美元。在上一年同期，該公司每股收益 2.13 美元。強生的收入與去年同期相比下降了 4.4%。作為一個集團，研究分析師預測，強生公佈本財年每股 10.5 收益。
Johnson & Johnson Dividend Announcement
強生公佈股息
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were issued a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.96%. Johnson & Johnson's payout ratio is currently 67.06%.
該公司最近還披露了季度股息，該股息於 3 月 7 日（星期二）支付。2 月 21 日（星期二）的股東記錄發出 1.13 美元的股息。除息日期為 2 月 17 日星期五。這代表按年化基礎計算的股息為 4.52 美元，收益率為 2.96％。強生的支付比率目前為 67.06%。
About Johnson & Johnson
關於強生
(Get Rating)
(取得評分)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.
Johnson & Johnson 是一家控股公司，從事醫療保健領域產品的研發、製造和銷售。它通過以下部分運作：消費者健康，藥品和醫療科技。消費者健康部門包括專注於皮膚健康/美容中使用的個人保健產品，非處方藥，嬰兒護理，口腔護理，婦女健康和傷口護理市場。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/20 – 3/24
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 5 Best Dividend Capture Stocks
- 獲取有關強生（JNJ）的研究報告的免費副本
- 市場節拍週的回顧 — 3 月 20 日 — 3/24
- 股息王原廠配件公司升級的利潤指導
- 底部是在埃森哲
- 11 股 2023 年最佳非必要消費品股票
- 5 個最佳股息捕捉股票
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
接收約翰遜日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Johnson 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。